Klinikum Chemnitz gGmbH
Chemnitz, Germany
26 recruiting
Showing 1–20 of 38 trials
Recruiting
Phase 2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company65 enrolled40 locationsNCT07015242
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled290 locationsNCT06252649
Recruiting
Phase 3
A Study of Daratumumab
Multiple Myeloma
Janssen Research & Development, LLC500 enrolled92 locationsNCT05438043
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC380 enrolled70 locationsNCT07230691
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Relapsed Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 3
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled179 locationsNCT05232916
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled381 locationsNCT05253651
Recruiting
Phase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled57 locationsNCT06847542
Recruiting
Phase 2Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled225 locationsNCT06712316
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled210 locationsNCT06801834
Recruiting
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
VEXAS Syndrome
Technische Universität Dresden500 enrolled17 locationsNCT06377462
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Primary Biliary CholangitisPBC
Mirum Pharmaceuticals, Inc.260 enrolled130 locationsNCT05050136
Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319
Recruiting
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company257 enrolled76 locationsNCT05993234
Recruiting
Phase 2
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
Waldenstrom MacroglobulinemiaTreatment Naive
Christian Buske80 enrolled14 locationsNCT05099471
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled329 locationsNCT06758401
Recruiting
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Acute Myeloid Leukemia (AML)
Technische Universität Dresden15,000 enrolled60 locationsNCT03188874
Recruiting
Phase 3
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Brain TumorGlioblastomaGBM+1 more
Ivy Brain Tumor Center450 enrolled95 locationsNCT06388733